WO2015104352A1 - Nanoparticules de protéine contenant de la flagelline utiles en tant que plate-forme de vaccin - Google Patents

Nanoparticules de protéine contenant de la flagelline utiles en tant que plate-forme de vaccin Download PDF

Info

Publication number
WO2015104352A1
WO2015104352A1 PCT/EP2015/050289 EP2015050289W WO2015104352A1 WO 2015104352 A1 WO2015104352 A1 WO 2015104352A1 EP 2015050289 W EP2015050289 W EP 2015050289W WO 2015104352 A1 WO2015104352 A1 WO 2015104352A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
flagellin
fla
formula
domain
Prior art date
Application number
PCT/EP2015/050289
Other languages
English (en)
Inventor
Peter Burkhard
Senthil Kumar RAMAN
Sara Maria PAULILLO
Matteo Piazza
Caroline KULANGARA
Christian MITTELHOLZER
Original Assignee
Alpha-O Peptides Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52347321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2015104352(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alpha-O Peptides Ag filed Critical Alpha-O Peptides Ag
Priority to CN201580004255.8A priority Critical patent/CN105960412B/zh
Priority to ES15700281T priority patent/ES2705588T3/es
Priority to AU2015205567A priority patent/AU2015205567B2/en
Priority to US15/110,449 priority patent/US10245318B2/en
Priority to EA201691202A priority patent/EA037258B8/ru
Priority to JP2016563253A priority patent/JP6652500B2/ja
Priority to EP15700281.7A priority patent/EP3092245B1/fr
Priority to CA2934472A priority patent/CA2934472A1/fr
Publication of WO2015104352A1 publication Critical patent/WO2015104352A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Abstract

La présente invention concerne des nanoparticules de protéines à auto-assemblage construites à partir de domaines d'oligomérisation appropriés et comportant, en outre, la flagelline de protéine de liaison TLR5 comme molécule adjuvant. L'invention concerne en outre l'utilisation de telles nanoparticules pour la vaccination.
PCT/EP2015/050289 2014-01-09 2015-01-09 Nanoparticules de protéine contenant de la flagelline utiles en tant que plate-forme de vaccin WO2015104352A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201580004255.8A CN105960412B (zh) 2014-01-09 2015-01-09 作为疫苗平台的含鞭毛蛋白的蛋白纳米颗粒
ES15700281T ES2705588T3 (es) 2014-01-09 2015-01-09 Nanopartículas proteicas que contienen flagelina como plataforma de vacunas
AU2015205567A AU2015205567B2 (en) 2014-01-09 2015-01-09 Flagellin-containing protein nanoparticles as a vaccine platform
US15/110,449 US10245318B2 (en) 2014-01-09 2015-01-09 Flagellin-containing protein nanoparticles as a vaccine platform
EA201691202A EA037258B8 (ru) 2014-10-16 2015-01-09 Флагеллин-содержащие белковые наночастицы для иммуномодуляции
JP2016563253A JP6652500B2 (ja) 2014-01-09 2015-01-09 ワクチンプラットフォームとしてのフラジェリン含有タンパク質ナノ粒子
EP15700281.7A EP3092245B1 (fr) 2014-01-09 2015-01-09 Nanoparticules protéiques contenant de la flagelline sous forme de plate-forme d'un vaccin
CA2934472A CA2934472A1 (fr) 2014-01-09 2015-01-09 Nanoparticules de proteine contenant de la flagelline utiles en tant que plate-forme de vaccin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14150600.6 2014-01-09
EP14150600 2014-01-09
EP14189264 2014-10-16
EP14189264.6 2014-10-16

Publications (1)

Publication Number Publication Date
WO2015104352A1 true WO2015104352A1 (fr) 2015-07-16

Family

ID=52347321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/050289 WO2015104352A1 (fr) 2014-01-09 2015-01-09 Nanoparticules de protéine contenant de la flagelline utiles en tant que plate-forme de vaccin

Country Status (8)

Country Link
US (1) US10245318B2 (fr)
EP (1) EP3092245B1 (fr)
JP (1) JP6652500B2 (fr)
CN (1) CN105960412B (fr)
AU (1) AU2015205567B2 (fr)
CA (1) CA2934472A1 (fr)
ES (1) ES2705588T3 (fr)
WO (1) WO2015104352A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048689A1 (fr) * 2015-09-16 2017-03-23 Artificial Cell Technologies, Inc. Compositions antimalariques et procédés
US9925252B2 (en) 2012-03-30 2018-03-27 Artificial Cell Technologies, Inc. Antigenic compositions and methods
WO2018154010A1 (fr) 2017-02-23 2018-08-30 Alpha-O Peptides Ag Nanoparticules de protéine à auto-assemblage encapsulant des acides nucléiques immunostimulateurs
WO2018172447A1 (fr) 2017-03-23 2018-09-27 Alpha-O Peptides Ag Nanoparticules de protéine à auto-assemblage avec des protéines à faisceau de six hélices intégrées
EP3807210A4 (fr) * 2018-06-13 2022-05-11 The Scripps Research Institute Vaccins nanoparticulaires comprenant de nouveaux constituants structuraux
EP3964532A4 (fr) * 2019-04-29 2023-06-07 Academy of Military Medical Sciences Protéine de fusion pouvant s'auto-assembler en nanoparticules protéiques et utilisation associée

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3575316A1 (fr) * 2014-08-27 2019-12-04 Amgen, Inc Variants d'inhibiteur tissulaire de la métalloprotéinase de type trois (timp-3), compositions et procédés
CN106362144B (zh) * 2016-10-31 2021-02-09 武汉三利生物技术有限公司 呼吸道合胞病毒疫苗
EP3758747A1 (fr) 2018-02-28 2021-01-06 University of Washington Vaccins à base de nanostructures auto-assemblables
US11213582B2 (en) 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
KR20200050264A (ko) * 2018-11-01 2020-05-11 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
WO2023108026A2 (fr) 2021-12-08 2023-06-15 Oakgrove Bio Llc Production biologique de peptides riches en histidine
CN114292314B (zh) * 2022-01-05 2022-08-09 武汉科前生物股份有限公司 一种鞭毛素突变体及其在制备非洲猪瘟抗原融合蛋白中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013144579A1 (fr) * 2012-03-30 2013-10-03 Heriot-Watt University Utilisation de flagelline en tant que vaccin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2540871C2 (ru) * 2008-02-01 2015-02-10 Альфа-О Пептидес Аг Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин
ES2594102T3 (es) * 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
CN103044530B (zh) * 2013-01-04 2014-07-09 扬州大学 一种可用作免疫佐剂的改良型鞭毛蛋白及其制备与应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013144579A1 (fr) * 2012-03-30 2013-10-03 Heriot-Watt University Utilisation de flagelline en tant que vaccin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIU GE ET AL: "Immunogenicity and Efficacy of Flagellin-Fused Vaccine Candidates Targeting 2009 Pandemic H1N1 Influenza in Mice", PLOS ONE, vol. 6, no. 6, June 2011 (2011-06-01), XP002725576, ISSN: 1932-6203 *
S. B. MIZEL ET AL: "Flagellin as an Adjuvant: Cellular Mechanisms and Potential", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 10, 15 November 2010 (2010-11-15), pages 5677 - 5682, XP055066659, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1002156 *
SALMAN HESHAM H ET AL: "Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination", VACCINE, vol. 27, no. 35, July 2009 (2009-07-01), pages 4784 - 4790, XP002725578, ISSN: 0264-410X *
YANG JINGYI ET AL: "Antigen replacement of domains D2 and D3 in flagellin promotes mucosal IgA production and attenuates flagellin-induced inflammatory response after intranasal immunization", HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 9, no. 5, May 2013 (2013-05-01), pages 1084 - 1092, XP002725577 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925252B2 (en) 2012-03-30 2018-03-27 Artificial Cell Technologies, Inc. Antigenic compositions and methods
AU2016322544B2 (en) * 2015-09-16 2022-08-25 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
CN108025052A (zh) * 2015-09-16 2018-05-11 人工细胞科技公司 抗疟疾组合物和方法
US9968665B2 (en) 2015-09-16 2018-05-15 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
IL257895B2 (en) * 2015-09-16 2024-03-01 Artificial Cell Tech Inc Preparations and methods against malaria
JP2018529684A (ja) * 2015-09-16 2018-10-11 アーティフィシャル セル テクノロジーズ インコーポレイテッド 抗マラリア組成物および方法
US10588954B2 (en) 2015-09-16 2020-03-17 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
WO2017048689A1 (fr) * 2015-09-16 2017-03-23 Artificial Cell Technologies, Inc. Compositions antimalariques et procédés
CN108025052B (zh) * 2015-09-16 2022-05-10 人工细胞科技公司 抗疟疾组合物和方法
IL257895B1 (en) * 2015-09-16 2023-11-01 Artificial Cell Tech Inc Preparations and methods against malaria
WO2018154010A1 (fr) 2017-02-23 2018-08-30 Alpha-O Peptides Ag Nanoparticules de protéine à auto-assemblage encapsulant des acides nucléiques immunostimulateurs
CN110996995A (zh) * 2017-03-23 2020-04-10 阿尔法-O肽股份公司 具有内置六螺旋束蛋白的自组装蛋白纳米粒子
WO2018172447A1 (fr) 2017-03-23 2018-09-27 Alpha-O Peptides Ag Nanoparticules de protéine à auto-assemblage avec des protéines à faisceau de six hélices intégrées
AU2019285048B2 (en) * 2018-06-13 2023-06-08 The Scripps Research Institute Nanoparticle vaccines with novel structural components
EP3807210A4 (fr) * 2018-06-13 2022-05-11 The Scripps Research Institute Vaccins nanoparticulaires comprenant de nouveaux constituants structuraux
EP3964532A4 (fr) * 2019-04-29 2023-06-07 Academy of Military Medical Sciences Protéine de fusion pouvant s'auto-assembler en nanoparticules protéiques et utilisation associée

Also Published As

Publication number Publication date
JP2017503857A (ja) 2017-02-02
US20160324958A1 (en) 2016-11-10
US10245318B2 (en) 2019-04-02
EP3092245B1 (fr) 2018-10-17
ES2705588T3 (es) 2019-03-26
JP6652500B2 (ja) 2020-02-26
CN105960412B (zh) 2021-04-27
AU2015205567A1 (en) 2016-07-14
CN105960412A (zh) 2016-09-21
CA2934472A1 (fr) 2015-07-16
AU2015205567B2 (en) 2019-04-04
EP3092245A1 (fr) 2016-11-16

Similar Documents

Publication Publication Date Title
EP3092245B1 (fr) Nanoparticules protéiques contenant de la flagelline sous forme de plate-forme d'un vaccin
JP6088123B2 (ja) ワクチンとして有用な自己会合ペプチドナノ粒子
US20230340031A1 (en) Self-assembling protein nanoparticles with built-in six-helix bundle proteins
Blokhina et al. A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles
US20210017238A1 (en) Antigenic OspA Polypeptides
KR20190056382A (ko) 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
JP7385680B2 (ja) 変異型ｒｓｖ ｆタンパク質及びその利用
US20140242104A1 (en) Self-assembling peptide nanoparticles as vaccines against infection with norovirus
Lee et al. Nanoglue: an alternative way to display cell-internalizing peptide at the spikes of hepatitis B virus core nanoparticles for cell-targeting delivery
CN114127101A (zh) 用于治疗或预防呼吸道感染的亚单位疫苗
WO2010092963A1 (fr) Transporteur de médicament et adjuvant et vaccin l'utilisant chacun
ES2713962T3 (es) Vacuna para prevenir la enfermedad de edema porcino
JP2024036461A (ja) 自己集合ペプチド骨格
JP7062595B2 (ja) 複合ポリペプチド単量体、細胞浸透機能を有する当該複合ポリペプチドの単量体の会合体、及び、当該会合体を有効成分とする皮下、皮内、経皮又は筋肉内投与用ノロウイルスコンポーネントワクチン
US20220119457A1 (en) Antigenic Multimeric Respiratory Syncytial Virus Polypeptides
EA037258B1 (ru) Флагеллин-содержащие белковые наночастицы для иммуномодуляции
WO2023064631A1 (fr) Ingénierie de liaison d'antigène à, et orientation sur, des adjuvants pour des réponses humorales améliorées et une immunofocalisation
Varner COPYRIGHT© 2017 BY CHAD VARNER

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15700281

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2934472

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2015700281

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015700281

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201691202

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2016563253

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15110449

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2015205567

Country of ref document: AU

Date of ref document: 20150109

Kind code of ref document: A